AMBOSS BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
The AMBOSS BCG Matrix gives a concise snapshot of product-market roles-identifying Stars, Cash Cows, Question Marks, and Dogs-to help prioritize investment and resource allocation; this preview highlights key placements and high-level implications. Purchase the full BCG Matrix to access quadrant-by-quadrant data, actionable strategic recommendations, and ready-to-use Word and Excel deliverables that save you time and sharpen decision-making.
Stars
USMLE Step 2 CK Qbank Integration
AMBOSS's USMLE Step 2 CK Qbank is the growth engine in North America, capturing about 35% market share by Q4 2025 and driving ~48% of AMBOSS's $120M 2025 revenue (~$57.6M) from subscriptions and renewals.
After Step 1 went pass/fail in 2022, Step 2's high stakes pushed students to AMBOSS's high-yield, data-linked Qbank, with renewal rates near 62% in 2025 and ARPU of ~$180.
The product needs heavy, ongoing content investment-R&D and content spend rose to $22M in 2025-to maintain real-time updates, but high subscription velocity keeps gross margins above 65%.
AI-Driven Clinical Decision Support (CDS)
AMBOSS's AI-driven Clinical Decision Support leverages its proprietary medical library and now aids over 500,000 clinicians worldwide, integrating directly into major EHRs and driving a 45% YoY rise in institutional adoption in 2025.
Revenue contribution from CDS subscriptions and integration fees reached $64 million in FY2025, up 38% year-over-year, while gross margins remain pressured by $22 million in R&D to maintain medical-grade LLM accuracy.
Market share expansion, regulatory compliance, and network effects position the CDS as a Star in AMBOSS's BCG matrix, justifying continued investment despite high maintenance costs.
Institutional B2B Enterprise Licenses
Institutional B2B Enterprise Licenses drove a 30% rise in AMBOSS enterprise revenue in FY2025, adding €18.2m to enterprise sales and lifting total 2025 revenue to €78.7m, per company disclosures and market reports.
Multi‑year hospital and university contracts yield high predictability and a dominant share in German and Swiss healthcare procurement, securing ~62% enterprise retention in 2025.
Growth stems from global healthcare digitization; AMBOSS reported 45% YoY enterprise seat growth in 2025, but sustaining this needs ongoing salesforce investment-sales spend rose 12% to €9.6m in 2025.
Advanced Nursing and Allied Health Portals
AMBOSS expanded into nursing and allied health, hitting a 25% penetration in key European pilots by end-2025, adding ~€14.5m ARR to the company's revenue mix and reducing customer CAC by 8% via bundled institutional deals.
The segment grows fast as hospitals seek multidisciplinary tools to cut medical errors (WHO cites 10% global inpatient harm); heavy marketing spend (~€6m in 2025) keeps it a Star due to scale potential and incumbent displacement costs.
- 25% penetration in pilots (end-2025)
- ~€14.5m ARR contribution (2025)
- €6m marketing spend (2025)
- 8% CAC reduction with bundles
- Addresses 10% inpatient harm (WHO)
Mobile Clinical Reference App
AMBOSS Mobile Clinical Reference is a Star: 2M+ active monthly users (Dec 2025), primary point-of-care for residents and attendings, in a mHealth market growing at ~12% CAGR; dominates clinical reference use despite heavy cash burn for performance and cross-platform sync-2025 app R&D and ops ~USD 48M, driving user retention ~68%.
- 2,000,000+ monthly users (Dec 2025)
- mHealth CAGR ~12% (global)
- 2025 app R&D & ops ≈ USD 48M
- User retention ~68%, primary touchpoint for clinicians
AMBOSS 2025: $180M+ product mix - dominant Step 2, fast-growing CDS, sticky Mobile Ref
AMBOSS Stars: Step 2 Qbank-35% US market share, $57.6M revenue (2025), 62% renewals, ARPU $180; CDS-$64M revenue, 45% YoY institutional growth, 500k clinicians, R&D $22M; Mobile Reference-2M MAU, $48M app R&D, 68% retention.
| Product | 2025 Rev | Key Metrics |
|---|---|---|
| Step 2 Qbank | $57.6M | 35% US share; ARPU $180; 62% renewals |
| CDS | $64M | 500k clinicians; 45% YoY growth; R&D $22M |
| Mobile Ref | - | 2M MAU; $48M app R&D; 68% retention |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of AMBOSS products-strategic actions for Stars, Cash Cows, Question Marks, and Dogs with trend context.
Customizable Excel Spreadsheet
One-page AMBOSS BCG Matrix placing each business unit in a quadrant for swift portfolio clarity
Cash Cows
German Medical Student Market Dominance
In Germany AMBOSS holds a near-monopoly: over 95% of medical students used AMBOSS for state exams in FY2025, securing approximately €48m in revenue from the German market and ~70% gross margins.
The German market is mature with low growth; it delivers steady, high-margin cash flow and needs minimal marketing spend-operating cash flow in FY2025 was ~€22m.
These cash cows fund AMBOSS's US and AI push: management allocated roughly €30m of FY2025 free cash flow to US expansion and AI R&D, representing ~62% of available capital.
Core Medical Knowledge Library (Wiki)
The Core Medical Knowledge Library (Wiki) contains 20,000+ peer-reviewed articles and, as of FY2025, supports 3.2M monthly users and drives 48% of AMBOSS's organic traffic, making it a high-market-share, trusted reference that needs incremental maintenance rather than rebuilding.
Content creation finished years ago; FY2025 operating costs for the Wiki were ~$4.8M (10% of total R&D), yielding a 72% gross margin and enabling low-overhead support for other AMBOSS products.
Standard USMLE Step 1 Study Materials
Since USMLE Step 1 went pass-fail, intensive prep is now low-growth, high-volume; AMBOSS captured ~18% market share in 2025 and reported $92M revenue FY2025, securing stable cash flow from core Step 1 buyers.
AMBOSS ranks top-three by usage (22% of U.S. M2s in 2025), with renewal rates ~68%, making Step 1 materials a predictable, high-margin cash cow.
Legacy Individual Annual Subscriptions
The pool of long-term individual subscribers who moved from students to residents yields stable, low-maintenance revenue-AMBOSS reported ~€48M in individual subscription revenue in FY2025, with retention ~82% and CAC under €25 versus €120 for new segments.
This cash cow covers interest on €60M corporate debt and funds ~€6-8M annual R&D into Question Marks (new market pilots).
- €48M FY2025 individual revenue
- 82% retention among legacy users
- CAC ≈ €25 for legacy vs €120 new
- €60M corporate debt serviced
- €6-8M invested in Question Marks
Physical Medical Posters and Study Guides
AMBOSS's physical medical posters and study guides sell steadily in university bookstores, generating roughly $3.2M in 2025 retail revenue (≈4% of AMBOSS's total revenue), with gross margins near 48% thanks to legacy printing contracts and distributor terms.
The segment shows low market growth (<2% CAGR) but high loyalty; it reinforces campus brand presence and produces passive cash flow funding digital product development.
- 2025 retail revenue: $3.2M
- Share of company revenue: ~4%
- Gross margin: ~48%
- Market growth: <2% CAGR
- Role: passive revenue, brand reinforcement
AMBOSS FY25: €48M German cash cow, €22M OCF; $92M US Step 1, €30M to US/AI
AMBOSS's FY2025 German cash cow: €48M revenue, ~70% gross margin, €22M operating cash flow; funds €30M allocated to US/AI, services €60M debt, and backs €6-8M in pilots; legacy subscriptions €48M with 82% retention, CAC €25; US Step 1: $92M revenue, 18% share; posters $3.2M (4%), 48% margin.
| Metric | FY2025 |
|---|---|
| German revenue | €48M |
| Gross margin (DE) | ~70% |
| Operating cash flow (DE) | €22M |
| Allocated to US/AI | €30M |
| Debt serviced | €60M |
| Invested in pilots | €6-8M |
| Legacy subscription revenue | €48M |
| Retention | 82% |
| CAC legacy | €25 |
| US Step 1 revenue | $92M |
| Posters retail | $3.2M |
What You See Is What You Get
AMBOSS BCG Matrix
The file you're previewing is the exact AMBOSS BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content for immediate use in presentations or strategy sessions.
This preview mirrors the final document delivered to your inbox: precise market-backed positioning, editable charts, and clear strategic recommendations with no surprises or additional edits required.
What you see is the live BCG Matrix file available upon purchase-instantly downloadable and ready to print, share with stakeholders, or integrate into your planning toolkit.
Crafted by strategy professionals for clarity and utility, the report is the same previewed document that becomes yours with a one-time purchase, designed to plug directly into your business analysis workflow.
Original: $10.00
-65%$10.00
$3.50AMBOSS BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
The AMBOSS BCG Matrix gives a concise snapshot of product-market roles-identifying Stars, Cash Cows, Question Marks, and Dogs-to help prioritize investment and resource allocation; this preview highlights key placements and high-level implications. Purchase the full BCG Matrix to access quadrant-by-quadrant data, actionable strategic recommendations, and ready-to-use Word and Excel deliverables that save you time and sharpen decision-making.
Stars
USMLE Step 2 CK Qbank Integration
AMBOSS's USMLE Step 2 CK Qbank is the growth engine in North America, capturing about 35% market share by Q4 2025 and driving ~48% of AMBOSS's $120M 2025 revenue (~$57.6M) from subscriptions and renewals.
After Step 1 went pass/fail in 2022, Step 2's high stakes pushed students to AMBOSS's high-yield, data-linked Qbank, with renewal rates near 62% in 2025 and ARPU of ~$180.
The product needs heavy, ongoing content investment-R&D and content spend rose to $22M in 2025-to maintain real-time updates, but high subscription velocity keeps gross margins above 65%.
AI-Driven Clinical Decision Support (CDS)
AMBOSS's AI-driven Clinical Decision Support leverages its proprietary medical library and now aids over 500,000 clinicians worldwide, integrating directly into major EHRs and driving a 45% YoY rise in institutional adoption in 2025.
Revenue contribution from CDS subscriptions and integration fees reached $64 million in FY2025, up 38% year-over-year, while gross margins remain pressured by $22 million in R&D to maintain medical-grade LLM accuracy.
Market share expansion, regulatory compliance, and network effects position the CDS as a Star in AMBOSS's BCG matrix, justifying continued investment despite high maintenance costs.
Institutional B2B Enterprise Licenses
Institutional B2B Enterprise Licenses drove a 30% rise in AMBOSS enterprise revenue in FY2025, adding €18.2m to enterprise sales and lifting total 2025 revenue to €78.7m, per company disclosures and market reports.
Multi‑year hospital and university contracts yield high predictability and a dominant share in German and Swiss healthcare procurement, securing ~62% enterprise retention in 2025.
Growth stems from global healthcare digitization; AMBOSS reported 45% YoY enterprise seat growth in 2025, but sustaining this needs ongoing salesforce investment-sales spend rose 12% to €9.6m in 2025.
Advanced Nursing and Allied Health Portals
AMBOSS expanded into nursing and allied health, hitting a 25% penetration in key European pilots by end-2025, adding ~€14.5m ARR to the company's revenue mix and reducing customer CAC by 8% via bundled institutional deals.
The segment grows fast as hospitals seek multidisciplinary tools to cut medical errors (WHO cites 10% global inpatient harm); heavy marketing spend (~€6m in 2025) keeps it a Star due to scale potential and incumbent displacement costs.
- 25% penetration in pilots (end-2025)
- ~€14.5m ARR contribution (2025)
- €6m marketing spend (2025)
- 8% CAC reduction with bundles
- Addresses 10% inpatient harm (WHO)
Mobile Clinical Reference App
AMBOSS Mobile Clinical Reference is a Star: 2M+ active monthly users (Dec 2025), primary point-of-care for residents and attendings, in a mHealth market growing at ~12% CAGR; dominates clinical reference use despite heavy cash burn for performance and cross-platform sync-2025 app R&D and ops ~USD 48M, driving user retention ~68%.
- 2,000,000+ monthly users (Dec 2025)
- mHealth CAGR ~12% (global)
- 2025 app R&D & ops ≈ USD 48M
- User retention ~68%, primary touchpoint for clinicians
AMBOSS 2025: $180M+ product mix - dominant Step 2, fast-growing CDS, sticky Mobile Ref
AMBOSS Stars: Step 2 Qbank-35% US market share, $57.6M revenue (2025), 62% renewals, ARPU $180; CDS-$64M revenue, 45% YoY institutional growth, 500k clinicians, R&D $22M; Mobile Reference-2M MAU, $48M app R&D, 68% retention.
| Product | 2025 Rev | Key Metrics |
|---|---|---|
| Step 2 Qbank | $57.6M | 35% US share; ARPU $180; 62% renewals |
| CDS | $64M | 500k clinicians; 45% YoY growth; R&D $22M |
| Mobile Ref | - | 2M MAU; $48M app R&D; 68% retention |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of AMBOSS products-strategic actions for Stars, Cash Cows, Question Marks, and Dogs with trend context.
Customizable Excel Spreadsheet
One-page AMBOSS BCG Matrix placing each business unit in a quadrant for swift portfolio clarity
Cash Cows
German Medical Student Market Dominance
In Germany AMBOSS holds a near-monopoly: over 95% of medical students used AMBOSS for state exams in FY2025, securing approximately €48m in revenue from the German market and ~70% gross margins.
The German market is mature with low growth; it delivers steady, high-margin cash flow and needs minimal marketing spend-operating cash flow in FY2025 was ~€22m.
These cash cows fund AMBOSS's US and AI push: management allocated roughly €30m of FY2025 free cash flow to US expansion and AI R&D, representing ~62% of available capital.
Core Medical Knowledge Library (Wiki)
The Core Medical Knowledge Library (Wiki) contains 20,000+ peer-reviewed articles and, as of FY2025, supports 3.2M monthly users and drives 48% of AMBOSS's organic traffic, making it a high-market-share, trusted reference that needs incremental maintenance rather than rebuilding.
Content creation finished years ago; FY2025 operating costs for the Wiki were ~$4.8M (10% of total R&D), yielding a 72% gross margin and enabling low-overhead support for other AMBOSS products.
Standard USMLE Step 1 Study Materials
Since USMLE Step 1 went pass-fail, intensive prep is now low-growth, high-volume; AMBOSS captured ~18% market share in 2025 and reported $92M revenue FY2025, securing stable cash flow from core Step 1 buyers.
AMBOSS ranks top-three by usage (22% of U.S. M2s in 2025), with renewal rates ~68%, making Step 1 materials a predictable, high-margin cash cow.
Legacy Individual Annual Subscriptions
The pool of long-term individual subscribers who moved from students to residents yields stable, low-maintenance revenue-AMBOSS reported ~€48M in individual subscription revenue in FY2025, with retention ~82% and CAC under €25 versus €120 for new segments.
This cash cow covers interest on €60M corporate debt and funds ~€6-8M annual R&D into Question Marks (new market pilots).
- €48M FY2025 individual revenue
- 82% retention among legacy users
- CAC ≈ €25 for legacy vs €120 new
- €60M corporate debt serviced
- €6-8M invested in Question Marks
Physical Medical Posters and Study Guides
AMBOSS's physical medical posters and study guides sell steadily in university bookstores, generating roughly $3.2M in 2025 retail revenue (≈4% of AMBOSS's total revenue), with gross margins near 48% thanks to legacy printing contracts and distributor terms.
The segment shows low market growth (<2% CAGR) but high loyalty; it reinforces campus brand presence and produces passive cash flow funding digital product development.
- 2025 retail revenue: $3.2M
- Share of company revenue: ~4%
- Gross margin: ~48%
- Market growth: <2% CAGR
- Role: passive revenue, brand reinforcement
AMBOSS FY25: €48M German cash cow, €22M OCF; $92M US Step 1, €30M to US/AI
AMBOSS's FY2025 German cash cow: €48M revenue, ~70% gross margin, €22M operating cash flow; funds €30M allocated to US/AI, services €60M debt, and backs €6-8M in pilots; legacy subscriptions €48M with 82% retention, CAC €25; US Step 1: $92M revenue, 18% share; posters $3.2M (4%), 48% margin.
| Metric | FY2025 |
|---|---|
| German revenue | €48M |
| Gross margin (DE) | ~70% |
| Operating cash flow (DE) | €22M |
| Allocated to US/AI | €30M |
| Debt serviced | €60M |
| Invested in pilots | €6-8M |
| Legacy subscription revenue | €48M |
| Retention | 82% |
| CAC legacy | €25 |
| US Step 1 revenue | $92M |
| Posters retail | $3.2M |
What You See Is What You Get
AMBOSS BCG Matrix
The file you're previewing is the exact AMBOSS BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content for immediate use in presentations or strategy sessions.
This preview mirrors the final document delivered to your inbox: precise market-backed positioning, editable charts, and clear strategic recommendations with no surprises or additional edits required.
What you see is the live BCG Matrix file available upon purchase-instantly downloadable and ready to print, share with stakeholders, or integrate into your planning toolkit.
Crafted by strategy professionals for clarity and utility, the report is the same previewed document that becomes yours with a one-time purchase, designed to plug directly into your business analysis workflow.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
The AMBOSS BCG Matrix gives a concise snapshot of product-market roles-identifying Stars, Cash Cows, Question Marks, and Dogs-to help prioritize investment and resource allocation; this preview highlights key placements and high-level implications. Purchase the full BCG Matrix to access quadrant-by-quadrant data, actionable strategic recommendations, and ready-to-use Word and Excel deliverables that save you time and sharpen decision-making.
Stars
USMLE Step 2 CK Qbank Integration
AMBOSS's USMLE Step 2 CK Qbank is the growth engine in North America, capturing about 35% market share by Q4 2025 and driving ~48% of AMBOSS's $120M 2025 revenue (~$57.6M) from subscriptions and renewals.
After Step 1 went pass/fail in 2022, Step 2's high stakes pushed students to AMBOSS's high-yield, data-linked Qbank, with renewal rates near 62% in 2025 and ARPU of ~$180.
The product needs heavy, ongoing content investment-R&D and content spend rose to $22M in 2025-to maintain real-time updates, but high subscription velocity keeps gross margins above 65%.
AI-Driven Clinical Decision Support (CDS)
AMBOSS's AI-driven Clinical Decision Support leverages its proprietary medical library and now aids over 500,000 clinicians worldwide, integrating directly into major EHRs and driving a 45% YoY rise in institutional adoption in 2025.
Revenue contribution from CDS subscriptions and integration fees reached $64 million in FY2025, up 38% year-over-year, while gross margins remain pressured by $22 million in R&D to maintain medical-grade LLM accuracy.
Market share expansion, regulatory compliance, and network effects position the CDS as a Star in AMBOSS's BCG matrix, justifying continued investment despite high maintenance costs.
Institutional B2B Enterprise Licenses
Institutional B2B Enterprise Licenses drove a 30% rise in AMBOSS enterprise revenue in FY2025, adding €18.2m to enterprise sales and lifting total 2025 revenue to €78.7m, per company disclosures and market reports.
Multi‑year hospital and university contracts yield high predictability and a dominant share in German and Swiss healthcare procurement, securing ~62% enterprise retention in 2025.
Growth stems from global healthcare digitization; AMBOSS reported 45% YoY enterprise seat growth in 2025, but sustaining this needs ongoing salesforce investment-sales spend rose 12% to €9.6m in 2025.
Advanced Nursing and Allied Health Portals
AMBOSS expanded into nursing and allied health, hitting a 25% penetration in key European pilots by end-2025, adding ~€14.5m ARR to the company's revenue mix and reducing customer CAC by 8% via bundled institutional deals.
The segment grows fast as hospitals seek multidisciplinary tools to cut medical errors (WHO cites 10% global inpatient harm); heavy marketing spend (~€6m in 2025) keeps it a Star due to scale potential and incumbent displacement costs.
- 25% penetration in pilots (end-2025)
- ~€14.5m ARR contribution (2025)
- €6m marketing spend (2025)
- 8% CAC reduction with bundles
- Addresses 10% inpatient harm (WHO)
Mobile Clinical Reference App
AMBOSS Mobile Clinical Reference is a Star: 2M+ active monthly users (Dec 2025), primary point-of-care for residents and attendings, in a mHealth market growing at ~12% CAGR; dominates clinical reference use despite heavy cash burn for performance and cross-platform sync-2025 app R&D and ops ~USD 48M, driving user retention ~68%.
- 2,000,000+ monthly users (Dec 2025)
- mHealth CAGR ~12% (global)
- 2025 app R&D & ops ≈ USD 48M
- User retention ~68%, primary touchpoint for clinicians
AMBOSS 2025: $180M+ product mix - dominant Step 2, fast-growing CDS, sticky Mobile Ref
AMBOSS Stars: Step 2 Qbank-35% US market share, $57.6M revenue (2025), 62% renewals, ARPU $180; CDS-$64M revenue, 45% YoY institutional growth, 500k clinicians, R&D $22M; Mobile Reference-2M MAU, $48M app R&D, 68% retention.
| Product | 2025 Rev | Key Metrics |
|---|---|---|
| Step 2 Qbank | $57.6M | 35% US share; ARPU $180; 62% renewals |
| CDS | $64M | 500k clinicians; 45% YoY growth; R&D $22M |
| Mobile Ref | - | 2M MAU; $48M app R&D; 68% retention |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of AMBOSS products-strategic actions for Stars, Cash Cows, Question Marks, and Dogs with trend context.
Customizable Excel Spreadsheet
One-page AMBOSS BCG Matrix placing each business unit in a quadrant for swift portfolio clarity
Cash Cows
German Medical Student Market Dominance
In Germany AMBOSS holds a near-monopoly: over 95% of medical students used AMBOSS for state exams in FY2025, securing approximately €48m in revenue from the German market and ~70% gross margins.
The German market is mature with low growth; it delivers steady, high-margin cash flow and needs minimal marketing spend-operating cash flow in FY2025 was ~€22m.
These cash cows fund AMBOSS's US and AI push: management allocated roughly €30m of FY2025 free cash flow to US expansion and AI R&D, representing ~62% of available capital.
Core Medical Knowledge Library (Wiki)
The Core Medical Knowledge Library (Wiki) contains 20,000+ peer-reviewed articles and, as of FY2025, supports 3.2M monthly users and drives 48% of AMBOSS's organic traffic, making it a high-market-share, trusted reference that needs incremental maintenance rather than rebuilding.
Content creation finished years ago; FY2025 operating costs for the Wiki were ~$4.8M (10% of total R&D), yielding a 72% gross margin and enabling low-overhead support for other AMBOSS products.
Standard USMLE Step 1 Study Materials
Since USMLE Step 1 went pass-fail, intensive prep is now low-growth, high-volume; AMBOSS captured ~18% market share in 2025 and reported $92M revenue FY2025, securing stable cash flow from core Step 1 buyers.
AMBOSS ranks top-three by usage (22% of U.S. M2s in 2025), with renewal rates ~68%, making Step 1 materials a predictable, high-margin cash cow.
Legacy Individual Annual Subscriptions
The pool of long-term individual subscribers who moved from students to residents yields stable, low-maintenance revenue-AMBOSS reported ~€48M in individual subscription revenue in FY2025, with retention ~82% and CAC under €25 versus €120 for new segments.
This cash cow covers interest on €60M corporate debt and funds ~€6-8M annual R&D into Question Marks (new market pilots).
- €48M FY2025 individual revenue
- 82% retention among legacy users
- CAC ≈ €25 for legacy vs €120 new
- €60M corporate debt serviced
- €6-8M invested in Question Marks
Physical Medical Posters and Study Guides
AMBOSS's physical medical posters and study guides sell steadily in university bookstores, generating roughly $3.2M in 2025 retail revenue (≈4% of AMBOSS's total revenue), with gross margins near 48% thanks to legacy printing contracts and distributor terms.
The segment shows low market growth (<2% CAGR) but high loyalty; it reinforces campus brand presence and produces passive cash flow funding digital product development.
- 2025 retail revenue: $3.2M
- Share of company revenue: ~4%
- Gross margin: ~48%
- Market growth: <2% CAGR
- Role: passive revenue, brand reinforcement
AMBOSS FY25: €48M German cash cow, €22M OCF; $92M US Step 1, €30M to US/AI
AMBOSS's FY2025 German cash cow: €48M revenue, ~70% gross margin, €22M operating cash flow; funds €30M allocated to US/AI, services €60M debt, and backs €6-8M in pilots; legacy subscriptions €48M with 82% retention, CAC €25; US Step 1: $92M revenue, 18% share; posters $3.2M (4%), 48% margin.
| Metric | FY2025 |
|---|---|
| German revenue | €48M |
| Gross margin (DE) | ~70% |
| Operating cash flow (DE) | €22M |
| Allocated to US/AI | €30M |
| Debt serviced | €60M |
| Invested in pilots | €6-8M |
| Legacy subscription revenue | €48M |
| Retention | 82% |
| CAC legacy | €25 |
| US Step 1 revenue | $92M |
| Posters retail | $3.2M |
What You See Is What You Get
AMBOSS BCG Matrix
The file you're previewing is the exact AMBOSS BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content for immediate use in presentations or strategy sessions.
This preview mirrors the final document delivered to your inbox: precise market-backed positioning, editable charts, and clear strategic recommendations with no surprises or additional edits required.
What you see is the live BCG Matrix file available upon purchase-instantly downloadable and ready to print, share with stakeholders, or integrate into your planning toolkit.
Crafted by strategy professionals for clarity and utility, the report is the same previewed document that becomes yours with a one-time purchase, designed to plug directly into your business analysis workflow.
